In summary, while our study sheds light on the potential role of IL-4 and IL-13 as biomarkers, the limitations, such as the small sample size and lack of an observed serum level decrease, underscore the need for further research to elucidate their true significance in assessing the treatment response in AD patients undergoing Dupilumab administration. This evidence concerns the gene IL13 and Alzheimer disease.